• 1
    Jaffe ES. World Health Organisation classification of tumours—pathology and genetics of tumours of the haemopoietic and lymphoid tissues. Lyons, France: IARC Press, 2004.
  • 2
    Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol. 1999; 17: 776783.
  • 3
    Schwartz R. Hodgkin's disease—time for a change. N Engl J Med. 1997; 337: 494496.
  • 4
    Marafioti T, Hummel M, Anagnostopoulos I, et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med. 1997; 337: 453458.
  • 5
    Ohno T, Stribley JA, Wu G, et al. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med. 1997; 337: 459466.
  • 6
    Russell KJ, Hoppe RT, Colby TV, et al. Lymphocyte predominant Hodgkin's disease: clinical presentation and results of treatment. Radiother Oncol. 1984; 1: 197205.
  • 7
    Yahalom J. Changing role and decreasing size: current trends in radiotherapy for Hodgkin's disease. Curr Oncol Rep. 2002; 4: 415423.
  • 8
    Orlandi E, Lazzarino M, Brusamolino E, et al. Nodular lymphocyte predominance Hodgkin's disease: long-term observation reveals a continuous pattern of recurrence. Leuk Lymphoma. 1997; 26: 359368.
  • 9
    Regula DP Jr., Hoppe RT, Weiss LM. Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. N Engl J Med. 1988; 318: 214219.
  • 10
    Mauch PM, Kalish LA, Marcus KC, et al. Long-term survival in Hodgkin's disease. Cancer J Sci Am. 1995; 1: 3342.
  • 11
    Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al. Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection—a study of the French Society of Pediatric Oncology. J Clin Oncol. 2003; 21: 29482952.
  • 12
    Wilder RB, Schlembach PJ, Jones D, et al. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer. 2002; 94: 17311738.
  • 13
    Borg-Grech A, Radford JA, Crowther D, et al. A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin's disease. J Clin Oncol. 1989; 7: 13031309.
  • 14
    Pappa VI, Norton AJ, Gupta RK, et al. Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases. Ann Oncol. 1995; 6: 559565.
  • 15
    Ha CS, Kavadi V, Dimopoulos MA, et al. Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria. Int J Radiat Oncol Biol Phys. 1999; 43: 329334.
  • 16
    Bodis S, Kraus MD, Pinkus G, et. al. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. J Clin Oncol. 1997; 15: 30603066.
  • 17
    Wirth A, Chao M, Corry J, et al. Mantle irradiation alone for clinical Stage I–II Hodgkin's disease: long term follow-up and analysis of prognostic factors in 261 patients. J Clin Oncol. 1999; 17: 230240.
  • 18
    Crennan E, D'Costa I, Liew KH, et al. Lymphocyte predominant Hodgkin's disease: a clinicopathologic comparative study of histologic and immunophenotypic subtypes. Int J Radiat Oncol Biol Phys. 1995; 31: 333337.
  • 19
    Barton M, Boyages J, Crennan E, et al. Radiotherapy for early infradiaphragmatic Hodgkin's disease: the Australasian experience. Radiother Oncol. 1996; 39: 17.
  • 20
    Barton M, Boyages J, Crennan E, et al. Radiation therapy for early stage Hodgkin's disease: Australasian patterns of care. Australasian Radiation Oncology Lymphoma Group. Int J Radiat Oncol Biol Phys. 1995; 31: 227236.
  • 21
    Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989; 7: 16301636.
  • 22
    MathSoft, Inc. S-PLUS 2000 [release 3]. Seattle: MathSoft Inc., 1999.
  • 23
    SPSS Inc. SPSS for Windows [release 11.0.1]. Chicago: SPSS, Inc., 2001.
  • 24
    Kalbfleisch JD. The statistical analysis of failure time data. Ann Oncol. 1980; 7: S109S113.
  • 25
    Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996; 17: 343346.
  • 26
    Schlembach PJ, Wilder RB, Jones D, et al. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. Cancer J. 2002; 8: 377383.
  • 27
    MacManus MP, Hoppe RT. Is radiotherapy curative for Stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996; 14: 12821290.
  • 28
    Denham JW, Denham E, Dear KB, et al. The follicular non-Hodgkin's lymphomas—I. The possibility of cure. Eur J Cancer. 1996; 32A: 470479.
  • 29
    Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a Phase 2 trial. Blood. 2003; 101: 42854289.
  • 30
    Rehwald U, Schulz H, Reiser M, et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a Phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood. 2003; 101: 420424.